Compare IONQ Inc (IONQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Zoetis Inc — how do they compare? IONQ Inc trades at $35.61 (market cap $12.78B), while Zoetis Inc trades at $74.92 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 2.5× IONQ Inc's market cap, and Zoetis Inc pays a 2.78% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| IONQ | ZTS | |
|---|---|---|
Market Cap | $12.78B | $31.95B |
Sector | Technology | Health |
52-Week High | $82.09 | $156.76 |
52-Week Low | $26.59 | $71.91 |
Enterprise Value | $10.78B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.24, down 1.55% with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth projections from $130M in 2025 to $187M in 2026, but remains unprofitable with a net loss of $510M in 2025. Analyst consensus is split with a $73.75 price target representing 115% upside potential. Recent news highlights IonQ's leadership in quantum computing platform development and government validation.
The stock offers significant upside potential based on analyst targets but faces execution risks in achieving profitability. High valuation multiples (P/E 89.18, P/S 58.73) reflect growth expectations, while negative cash flow from operations and competitive threats in quantum computing present substantial risks for investors.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
